Alternative Proteins / Molecular Farming / FoodTech
Strategic Profile
The company's technological approach aims to achieve the cost structure of plant-based solutions with the organoleptic properties of animal-based ones, leveraging technology developed over more than a decade. Product offerings include bioengineered safflower oil with gamma-linolenic acid (GLA), a soybean platform for producing pig proteins, and soy-based texturized products as meat alternatives.
Cyborg Score Rationale
Recent positive crushing results from the GLASO1 safflower platform confirmed 45% GLA concentrations and represent a major operational milestone validating commercial-scale performance. However, as of February 11, 2026, the stock trades at $5.00 with a market cap of only $3.63M, indicating significant market challenges despite technological progress.
Top Insights
USDA-APHIS approval for PiggySooy™ marks a pivotal regulatory milestone in the biotech landscape.
GLASO™ secured offtake agreements with major global CPG food and petfood companies plus R&D collaboration with Bunge.
In April 2025, the company entered into a Business Combination Agreement with Bioceres Group in an all-stock transaction.
FY2024 revenue was approximately $6M driven by soy protein ingredient business with controlled cash burn.
Named Competitors
Cultured Meat Products — Produces cultured meat from cells for fine-dining restaurants
Cultivated Meat — Develops cultivated meat using genetic engineering-free processes
Plant-Based Proteins — Competitor in alternative protein segment